Lu-177生长抑素类似物与PSMA治疗中基于个体化影像的骨髓剂量学:新型混合影像方案研究
该研究纳入5例接受7.4 GBq Lu-177-Octreotate治疗的患者和5例接受3.7 GBq Lu-177-PSMA-617治疗的患者,比较混合方案(三次腹部定量SPECT联合单次全身平面显像)与参考方案(序贯全身平面显像联合序贯定量SPECT)估算骨髓吸收剂量的差异。结果显示,若单次全身平面显像在注射后48或72小时采集,两种治疗的骨髓剂量学估算均可行。
要点
- 混合方案用三次腹部定量SPECT加单次全身平面显像估算骨髓剂量。
- Lu-177-Octreotate治疗中,HP72与参考方案中位差异为1%(0-5%)。
- Lu-177-PSMA-617治疗中,HP48与参考方案中位差异为3%(0-6%)。
核心结论
- 对于Lu-177-Octreotate和Lu-177-PSMA-617治疗,若单次全身平面显像在注射后48或72小时采集,序贯定量SPECT联合单次全身平面显像的骨髓剂量学估算可行。
- 考虑定量Lu-177成像和使用标准化器官水平S值的骨髓剂量学不确定性,混合方案的可靠性可被接受。
研究设计与样本
- 研究纳入5例接受7.4 GBq Lu-177-Octreotate治疗的患者和5例接受3.7 GBq Lu-177-PSMA-617治疗的患者。
- 每例患者在注射后24小时(含CT)、48小时和72小时进行全身平面显像和腹部SPECT采集。
- 在注射后30分钟、80分钟、24小时、48小时和72小时采集血样。
- 参考方案从序贯全身平面显像通过单指数拟合和质量缩放器官水平S值估算骨髓吸收剂量。
- 混合方案将定量SPECT数据的单指数拟合与注射后24、48或72小时采集的一次全身平面显像的活度进行缩放(HP24、HP48、HP72)。
主要发现
- 与参考方案相比,Lu-177-Octreotate治疗中,HP24、HP48和HP72的总骨髓吸收剂量中位差异分别为13%(9-17%)、8%(4-15%)和1%(0-5%)。
- 与参考方案相比,Lu-177-PSMA-617治疗中,HP24、HP48和HP72的总骨髓吸收剂量中位差异分别为10%(2-20%)、3%(0-6%)和2%(0-6%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The bone marrow (BM) is a main organ at risk in Lu-177-PSMA-617 therapy of prostate cancer and Lu-177-Octreotate therapy of neuroendocrine tumours. BM dosimetry is challenging and time-consuming, as different sequential quantitative measurements must be combined. The BM absorbed dose from the remainder of the body (ROB) can be determined from sequential whole-body planar (WB-P) imaging, while quantitative Lu-177-SPECT allows for more robust tumour and organ absorbed doses. The aim was to investigate a time-efficient and patient-friendly hybrid protocol (HP) for the ROB absorbed dose to the BM. It combines three abdominal quantitative SPECT (QSPECT) scans with a single WB-P acquisition and was compared with a reference protocol (RP) using sequential WB-P in combination with sequential QSPECT images. We investigated five patients receiving 7.4 GBq Lu-177-Octreotate and five patients treated with 3.7 GBq Lu-177-PSMA-617. Each patient had WB-P and abdominal SPECT acquisitions 24 (+ CT), 48, and 72 h post-injection. Blood samples were drawn 30 min, 80 min, 24 h, 48 h, and 72 h post-injection. BM absorbed doses from the ROB were estimated from sequential WB-P images (RP), via a mono-exponential fit and mass-scaled organ-level S values. For the HP, a mono-exponential fit on the QSPECT data was scaled with the activity of one WB-P image acquired either 24, 48, or 72 h post-injection (HP24, HP48, HP72). Total BM absorbed doses were determined as a sum of ROB, blood, major organ, and tumour contributions. RESULTS: Compared with the RP and for Lu-177-Octreotate therapy, median differences of the total BM absorbed doses were 13% (9-17%), 8% (4-15%), and 1% (0-5%) for the HP24, HP48, and HP72, respectively. For Lu-177-PSMA-617 therapy, total BM absorbed doses deviated 10% (2-20%), 3% (0-6%), and 2% (0-6%). CONCLUSION: For both Lu-177-Octreotate and Lu-177-PSMA-617 therapy, BM dosimetry via sequential QSPECT imaging and a single WB-P acquisition is feasible, if this WB-P image is acquired at a late time point (48 or 72 h post-injection). The reliability of the HP can be well accepted considering the uncertainties of quantitative Lu-177 imaging and BM dosimetry using standardised organ-level S values.
引用
- Gosewisch A, Delker A, Tattenberg S, et al. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res. 2018. PMID: 30076556. doi:10.1186/s13550-018-0427-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。